Structure-activity studies of B1 receptor-related peptides: Antagonists

Hypertension

Volumn 28, Issue 5, 1996, Pages 833-839

  Gobeil, Fernand ^a   Neugebauer, Withold ^a   Filteau, Catherine ^a   Jukic, Daniela ^a   Nsa Allogho, Susanne ^a   Pheng, Leng Hong ^a   Nguyen Le, Xuan Khai ^a   Blouin, Daniel ^b   Regoli, Domenico ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

adrenergic antagonists; B1 receptors; guinea pigs; human; kinins; rabbits

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ DERIVATIVE; BRADYKININ[8 LEUCINE 9 DEARGININE]; DIPEPTIDYL CARBOXYPEPTIDASE; ICATIBANT; SYNTHETIC PEPTIDE;

ANIMAL TISSUE; AORTA; ARTICLE; BIOASSAY; DEGRADATION; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN TISSUE; ILEUM; JUGULAR VEIN; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; UMBILICAL VEIN;

EID: 0029974038     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.5.833     Document Type: Article

References (36)

1. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci. 1993;16:99-104.
2. 9-bradykinin-mediated hyperalgesia in the rat by inflammatory stimuli. Braz J Med Biol Res. 1994;27:1793-1802.
3. Alvarez AL, Delorenzy A, Santajuliana D, Finkielman S, Nahmod VE, Pirola CJ. Central bradykininergic system in normotensive and hypertensive rats. Clin Sci. 1992;82:513-519.
4. 1 de la bradykinine au niveau de la veine porte de rat diabétique. Médecine/Sciences. 1995;11(suppl 2):15. Abstract.
5. 2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol. 1996;74:586-589.
6. 1 receptors: a review. Immunopharmacology. 1995;30:1-26.
7. Regoli D, Barabé J, Park WK. Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol. 1977;55:855-867.
8. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
9. Erdös EG, Skidgel RA. The unusual substrate specificity and the distribution of human angiotensin I converting enzyme. Hypertension. 1986;8:34-37.
10. Gobeil F, Pheng LH, Badini I, Nguyen-Le XK, Pizard A, Rizzi A, Blouin D, Regoli D. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol. 1996;118:289-294.
11. Gaudreau P, Barabé J, St-Pierre S, Regoli D. Pharmacological studies of kinins in venous smooth muscles. Can J Physiol Pharmacol. 1981;59:371-379.
12. Furchgott RF, Bhadrakom S. Reaction of strips of rabbit aorta to epinephrine isopropyl-arterenol and other drugs. J Pharmacol Exp Ther. 1953;108:124-143.
13. Rang HP. Stimulant actions of volatile anaesthetics on smooth muscle. Br J Pharmacol. 1964;22:356-365.
14. Schild HO. pA, a new scale for the measurement of drug antagonism. Br J Pharmacol. 1947;2:189-206.
15. 1 receptors for kinins. J Pharmacol Exp Ther. 1993;266: 192-198.
16. 2 receptors in the rabbit and the guinea pig. Can J Physiol Pharmacol. 1996;74:137-144.
17. 1 receptor antagonist. Eur J Pharmacol. 1991;205:217-218.
18. Drapeau G, Regoli D. Synthesis of bradykinin analogues. Methods Enzymol. 1988;163:263-272.
19. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature and symbolism for amino acids and peptides. Eur J Biochem. 1983;138:9-37.
20. Vavrek RJ, Stewart JM. New bradykinin antagonists peptides as tools for the study of the kallikrein-kinin system. In: Iimura O, Margolius HS, eds. Renal Function, Hypertension and Kallikrein-Kinin System. Tokyo, Japan: University of Tokyo Press; 1988:85-89.
21. 2 receptor characterization. Trends Pharmacol Sci. 1990;11:156-161.
22. 2-receptor antagonists. Hypertension. 1991;17:107-115.
23. 7-substituted peptide bradykinin antagonists are not substrates for kininase II. Peptides. 1989;10:109-112.
24. Lévesque L, Harvey N, Rioux F, Drapeau G, Marceau F. Development of a binding assay for the B, receptors for kinins. Immunopharmacology. 1995;29:141-147.
25. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer DL, Hess JF. Expression cloning of a human B, bradykinin receptor. J Biol Chem. 1994;269:21583-21586.
26. 3)-lysyl-bradykinin released from human kininogens by human urinary kallikrein. FEBS Lett. 1988;232: 395-398.
27. Kato H, Matsumuara Y, Maeda H. Isolation and identification of hydroxyproline analogues of bradykinin in human urine. FEBS Lett. 1988;232:252-254.
28. Rhaleb NE, Drapeau G, Dion S, Jukic D, Rouissi NE, Regoli D. Structure-activity studies on bradykinin and related peptides: agonists. Br J Pharmacol. 1990;99:445-448.
29. 1 receptor activators and blockers in isolated vessels. Eur J Pharmacol. 1986;127:219-224.
30. Hilgenfeldt U, Linke R, Riester U, König W, Breipohl G. Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal Biochem. 1995;228:35-41.
31. Stewart JM, Vavrek RJ. Chemistry of peptide B2 bradykinin antagonists. In: Burch RM, ed. Bradykinin Antagonists: Basic and Clinical Research. New York, NY: Marcel Dekker; 1991:51-96.
32. Ferreira SH, Vane JR. The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cats. Br J Pharmacol. 1967;108:124-143.
33. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J, Scholkens BA. HOE 140, a new potent and long-acting bradykinin antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
34. Rhaleb NE, Gobeil F, Regoli D. Non-selectivity of new bradykinin antagonists for B, receptor. Life Sci. 1992;51:125-129.
35. 2 subtypes. Life Sci. 1994;55:735-749.
36. Regoli D, Pheng LH, Nsa Allogho S, Nguyen-Le XK, Gobeil F. Receptors for kinins: from classical pharmacology to molecular biology. Immunopharmacol. 1996;33:24-31.